RAINBOW CHILDRENS MED Latest Share Price (RAINBOW)
TODAY IN ONE LINE
RAINBOW fell 1.3% on average volume, lagging Nifty's 0.3% move.
With a market cap of ₹14,702.21 Cr., it trades at a P/E of 51.52. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
RAINBOW CHILDRENS MED flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 39.1% YoY
- ●High Capital EfficiencyROCE of 18.2% indicating pricing power
- ●Healthy Operating MarginsOPM is structurally strong at 26.2%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.01x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 12.7% YoY
- ●Expensive ValuationTrading at a high P/E ratio of 51.5x
- ●Low Promoter HoldingPromoters hold only 0.2%
- ●FII SellingFII holding decreased by 1.21% QoQ
- ●Promoter SellingPromoter holding decreased by 49.66% QoQ
Latest RAINBOW CHILDRENS MED News
What changed recently?
Recent events, corporate actions, and announcements.
RAINBOW CHILDRENS MED valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for RAINBOW CHILDRENS MED, framed against the sector median so the premium or discount is obvious at a glance.
RAINBOW CHILDRENS MED trades at a P/E of 51.52× and P/B of 8.92×, against the Healthcare sector median P/E of 45.85×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
RAINBOW CHILDRENS MED technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for RAINBOW CHILDRENS MED — derived from the latest tape, not yesterday's close.
RAINBOW CHILDRENS MED last traded at ₹1,454.7 with an intraday range of ₹1,447.4–₹1,494.9 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1454.70| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1578.93 | +124.23 | +8.54% |
| R3 | 1531.43 | +76.73 | +5.27% |
| R2 | 1513.17 | +58.47 | +4.02% |
| R1 | 1483.93 | +29.23 | +2.01% |
| PIVOT | 1465.67 | 10.97 | 0.75% |
| CURRENT | 1454.70 | — | — |
| S1 | 1436.43 | -18.27 | -1.26% |
| S2 | 1418.17 | -36.53 | -2.51% |
| S3 | 1388.93 | -65.77 | -4.52% |
| S4 | 1341.43 | -113.27 | -7.79% |
RAINBOW is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹1470.2–₹1494.9
Trading Inside opening range
RAINBOW CHILDRENS MED financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for RAINBOW CHILDRENS MED — consolidated or standalone — with margins, YoY growth and key ratios inline.
RAINBOW CHILDRENS MED reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹14,702.21 Cr. and reported EPS of ₹5.19.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,516 | 1,703 ▲ 12.4% |
| Sales Growth YoY %Derived | 16.88% | 12.35% |
| Other Income | 51 | 44 ▼ 14.2% |
| Total Income | 1,567 | 1,747 ▲ 11.5% |
| 195 | 227 ▲ 16.5% | |
| Gross ProfitDerived | 1,321 | 1,476 ▲ 11.7% |
| Gross Margin %Derived | 87.14% | 86.67% |
| 831 | 932 ▲ 12.1% | |
| EBITDA (Operating Profit)Derived | 490 | 544 ▲ 11.1% |
| OPM %Derived | 32.32% | 31.95% |
| 211 | 227 ▲ 7.5% | |
| Profit Before Tax (PBT) | 330 | 358 ▲ 8.6% |
| 86 | 77 ▼ 10.6% | |
| Effective Tax %Derived | 25.99% | 21.41% |
| Total Profit for Period | 244 | 282 ▲ 15.3% |
| Less: Non-controlling Interests | 1 | 3 ▲ 301.1% |
| Net Profit (Owner's PAT)Derived | 243 | 278 ▲ 14.3% |
| Net Profit Margin %Derived | 16.06% | 16.34% |
| PAT Growth YoY %Derived | 12.18% | 14.34% |
| Earnings Per Share (EPS ₹) | 23.97 | 27.41 ▲ 14.4% |
| Diluted Shares Outstanding (Cr) | 10 | 10 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -0 | -1 ▼ 1075.4% |
| Total Expenses (incl. D&A & Interest) | 1,237 | 1,389 ▲ 12.3% |
| Material Cost % of RevenueDerived | 12.86% | 13.33% |
| Employee Cost % of RevenueDerived | 13.61% | 13.71% |
| Other Cost % of RevenueDerived | 41.21% | 41.01% |
| Interest Coverage (x)Derived | 4.85x | 5.07x |
| Period | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|
| Revenue from Operations | 974 | 1,174 ▲ 20.5% | 1,297 ▲ 10.5% | 1,516 ▲ 16.9% | 1,703 ▲ 12.4% | |
| Sales Growth YoY %Derived | — | 20.52% | 10.51% | 16.88% | 12.35% | |
| Other Income | 19 | 31 ▲ 63.0% | 37 ▲ 20.1% | 51 ▲ 37.6% | 44 ▼ 14.2% | |
| Total Income | 993 | 1,204 ▲ 21.3% | 1,334 ▲ 10.8% | 1,567 ▲ 17.5% | 1,747 ▲ 11.5% | |
195 | 158 ▼ 18.7% | 165 ▲ 4.4% | 195 ▲ 17.9% | 227 ▲ 16.5% | ||
| Gross ProfitDerived | 779 | 1,015 ▲ 30.3% | 1,132 ▲ 11.5% | 1,321 ▲ 16.7% | 1,476 ▲ 11.7% | |
| Gross Margin %Derived | 80.00% | 86.51% | 87.26% | 87.14% | 86.67% | |
474 | 619 ▲ 30.5% | 703 ▲ 13.5% | 831 ▲ 18.3% | 932 ▲ 12.1% | ||
| EBITDA (Operating Profit)Derived | 305 | 396 ▲ 30.0% | 429 ▲ 8.2% | 490 ▲ 14.2% | 544 ▲ 11.1% | |
| OPM %Derived | 31.31% | 33.78% | 33.07% | 32.32% | 31.95% | |
136 | 145 ▲ 6.6% | 171 ▲ 17.6% | 211 ▲ 23.2% | 227 ▲ 7.5% | ||
| Profit Before Tax (PBT) | 187 | 282 ▲ 50.4% | 295 ▲ 4.6% | 330 ▲ 11.9% | 358 ▲ 8.6% | |
49 | 69 ▲ 42.6% | 77 ▲ 10.3% | 86 ▲ 12.1% | 77 ▼ 10.6% | ||
| Effective Tax %Derived | 25.98% | 24.63% | 25.96% | 25.99% | 21.41% | |
| Total Profit for Period | 139 | 212 ▲ 53.1% | 218 ▲ 2.8% | 244 ▲ 11.9% | 282 ▲ 15.3% | |
| Less: Non-controlling Interests | 0 | 2 ▲ 279.1% | 1 ▼ 16.7% | 1 ▼ 37.6% | 3 ▲ 301.1% | |
| Net Profit (Owner's PAT)Derived | 138 | 211 ▲ 52.5% | 217 ▲ 2.9% | 243 ▲ 12.2% | 278 ▲ 14.3% | |
| Net Profit Margin %Derived | 14.20% | 17.97% | 16.73% | 16.06% | 16.34% | |
| PAT Growth YoY %Derived | — | 52.48% | 2.93% | 12.18% | 14.34% | |
| Earnings Per Share (EPS ₹) | 13.62 | 20.77 ▲ 52.5% | 21.38 ▲ 2.9% | 23.97 ▲ 12.1% | 27.41 ▲ 14.4% | |
| Diluted Shares Outstanding (Cr) | 10 | 10 ▲ 0.0% | 10 ▲ 0.0% | 10 ▲ 0.0% | 10 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 1 | 0 ▼ 57.7% | 1 ▲ 207.4% | -0 ▼ 104.6% | -1 ▼ 1075.4% | |
| Total Expenses (incl. D&A & Interest) | 805 | 923 ▲ 14.6% | 1,039 ▲ 12.6% | 1,237 ▲ 19.0% | 1,389 ▲ 12.3% | |
| Material Cost % of RevenueDerived | 20.00% | 13.49% | 12.74% | 12.86% | 13.33% | |
| Employee Cost % of RevenueDerived | 11.92% | 12.28% | 13.58% | 13.61% | 13.71% | |
| Other Cost % of RevenueDerived | 36.77% | 40.46% | 40.60% | 41.21% | 41.01% | |
| Interest Coverage (x)Derived | 4.17x | 5.55x | 5.36x | 4.85x | 5.07x |
RAINBOW CHILDRENS MED segment analysis : revenue and profit mix.
Disclosed business segments at RAINBOW CHILDRENS MED with their share of revenue and profit, switchable between consolidated and standalone reporting.
RAINBOW CHILDRENS MED discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for RAINBOW CHILDRENS MED.
Our AI distills the core fundamental drivers supporting RAINBOW CHILDRENS MED, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
RAINBOW CHILDRENS MED's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 67 (~1.5× the sector multiple of 45.9) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 10% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.12%.
RAINBOW CHILDRENS MED peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — RAINBOW CHILDRENS MED is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
RAINBOW CHILDRENS MED chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for RAINBOW CHILDRENS MED — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
RAINBOW CHILDRENS MED delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for RAINBOW CHILDRENS MED over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in RAINBOW CHILDRENS MED stood at 53.1% of traded volume, against a 20-day average of 53.8%.
RAINBOW CHILDRENS MED announcements: results, concalls, ratings, M&A.
Filings RAINBOW CHILDRENS MED sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
RAINBOW CHILDRENS MED files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 144 documents below.
General Updates
RAINBOW: Rainbow Children's Medicare Limited has informed the Exchange about Commencement of operations at Guntur, Andhra Pradesh.
Analysts/Institutional Investor Meet/Con. Call Updates
Rainbow Childrens Medicare Limited has informed the Exchange about Schedule of meet of Analyst/Institutional Investors Group Meetings.
Resignation of Director/KMP/SMP
Rainbow Childrens Medicare Limited has informed the Exchange about Resignation of Director/KMP/SMP
Resignation
RAINBOW: Rainbow Children's Medicare Limited has informed the Exchange regarding Resignation of Mr. Srinath Metla as Senior Management Personnel of…
Resignation of Director/KMP/SMP
Rainbow Childrens Medicare Limited has informed the Exchange about Resignation of Director/KMP/SMP
Investor decks & rating reports.
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Investor Presentation
Investor Presentation
RAINBOW CHILDRENS MED dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue RAINBOW CHILDRENS MED has declared, sequenced by announce and record date.
RAINBOW CHILDRENS MED corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About RAINBOW CHILDRENS MED: business, sector, key facts.
What RAINBOW CHILDRENS MED does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
RAINBOW CHILDRENS MED operates in the Hospital industry under the Healthcare sector, listed as NSE: RAINBOW, BSE: 543524.
Rainbow Children's Medicare Limited (RAINBOW) is a prominent healthcare provider in India, specializing in pediatric and women's health services. The company operates a network of multi-specialty hospitals, focusing on delivering high-quality medical care to children and women across various stages of life. Their comprehensive approach encompasses a broad range of services, ensuring patients receive holistic and specialized attention.
A core component of RAINBOW's business is its pediatric care services offered under the "Rainbow Children's Hospital" brand. This includes critical care units such as newborn and pediatric intensive care units (NICU and PICU), catering to infants and children requiring specialized medical attention. Further, they provide a wide array of multi-specialty pediatric services, addressing various health concerns across different age groups. They also offer advanced quaternary care, which is typically reserved for complex and life-threatening conditions, notably including multi-organ transplantation procedures. This signifies their commitment to providing comprehensive and cutting-edge treatment options for children with severe illnesses.
Complementing their pediatric services, RAINBOW offers comprehensive women's healthcare services under the "Birthright" brand. This encompasses a full spectrum of perinatal care, supporting women throughout pregnancy and childbirth. This includes both routine and complex obstetric care, addressing a wide range of needs and complications. Their expertise extends to multi-disciplinary fetal care, where specialists from diverse medical backgrounds collaborate to provide the best possible care for the mother and unborn child. Services also extend to perinatal genetic and fertility support, assisting couples in conceiving and having healthy pregnancies. In addition to these services, Birthright provides a diverse range of gynecological treatments, catering to the overall health and well-being of women.
Beyond direct patient care, RAINBOW is also involved in medical education and training. They operate a private DNB (Diplomate of National Board) training program for pediatrics, offering postgraduate and fellowship opportunities. This program plays a vital role in developing future healthcare professionals and strengthening the medical workforce, contributing significantly to the growth of pediatric expertise in India. This commitment to education ensures a consistent supply of skilled professionals to maintain the high standards of care they provide.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- DR AGARWALS HEALTH CARE L (AGARWALEYE) Share PricePeer
- APOLLO HOSPITALS ENTER L (APOLLOHOSP) Share PricePeer
- ARTEMIS MED SERVICE (ARTEMISMED) Share PricePeer
- ASTER DM QUALITY CARE (ASTERDM) Share PricePeer
- FORTIS HEALTHCARE (FORTIS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about RAINBOW CHILDRENS MED (RAINBOW).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of RAINBOW CHILDRENS MED (RAINBOW)?
The current share price of RAINBOW CHILDRENS MED (RAINBOW) is ₹1,454.70. Today, the stock has declined by ₹18.70 (1.27%), trading in a range of ₹1,447.40 to ₹1,494.90. The stock opened at ₹1,473.40 with a trading volume of 99,805 shares.
02Is RAINBOW CHILDRENS MED stock a good investment for long-term?
RAINBOW CHILDRENS MED can be considered for long-term investment based on several factors. The company has a market capitalization of ₹14,702.21 Cr., P/E ratio of 51.52, ROE of 14.8%, and ROCE of 18.17%. The dividend yield stands at 0.24%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of RAINBOW CHILDRENS MED stock?
The 52-week high price of RAINBOW CHILDRENS MED (RAINBOW) is ₹1,610.00, while the 52-week low is ₹1,084.00. Currently trading at ₹1,454.70, the stock is 34.2% above its 52-week low and 9.65% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy RAINBOW CHILDRENS MED stock at the current price?
Whether to buy RAINBOW CHILDRENS MED stock at ₹1,454.70 depends on multiple factors. The stock is currently trading with a P/E ratio of 51.52 and P/B ratio of 8.92. Today's performance shows a loss of 1.27%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of RAINBOW CHILDRENS MED and when is the next dividend?
RAINBOW CHILDRENS MED offers a dividend yield of 0.24%, which means for every ₹100 invested at the current price of ₹1,454.70, you can expect to receive approximately ₹0.24 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of RAINBOW CHILDRENS MED?
RAINBOW CHILDRENS MED's key financial metrics include: P/E Ratio: 51.52, P/B Ratio: 8.92, ROE: 14.8%, ROCE: 18.17%, Dividend Yield: 0.24%, EPS: ₹5.19, Book Value: ₹163.80, and Debt-to-Equity: 0.01. The company's market cap stands at ₹14,702.21 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is RAINBOW CHILDRENS MED stock performing today in the market?
RAINBOW CHILDRENS MED stock opened at ₹1,473.40 and is currently trading at ₹1,454.70, showing a decline of ₹18.70 (1.27%). The intraday high is ₹1,494.90 and low is ₹1,447.40. The trading volume stands at 99,805 shares, indicating moderate market participation today.
08What is the P/E ratio of RAINBOW CHILDRENS MED and what does it indicate?
RAINBOW CHILDRENS MED has a Price-to-Earnings (P/E) ratio of 51.52, which means investors are willing to pay 51.52 for every ₹1 of earnings. With an EPS of ₹5.19, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about RAINBOW CHILDRENS MED (RAINBOW) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.